Medical Device Safety and Recalls: Cybersecurity Vulnerabilities of Hospira Symbiq Infusion System: FDA Safety Communication

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Medical Device Safety and Recalls: Cybersecurity Vulnerabilities of Hospira Symbiq Infusion System: FDA Safety Communication

Today the FDA issued a Safety Communication on cybersecurity vulnerabilities of the Hospira Symbiq Infusion System.

Hospira and an independent researcher confirmed that it is possible to access the Symbiq Infusion System remotely through a hospital’s network. This could allow unauthorized users to control the infusion pump and change the dosage it delivers, potentially leading to over- or under-infusion of critical patient therapies.

The FDA and Hospira are not aware of any patient adverse events or unauthorized access of a Symbiq Infusion System in a health care setting. Health care facilities can reduce the risk of unauthorized access by transitioning to an alternative infusion pump and implementing recommendations from the FDA Safety Communication.

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received by taking our Customer Service Survey.

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420